Maria Dung Cao1, Beathe Sitter1,
Tone Frost Bathen1, Per Eystein Lnning2,3, Steinar
Lundgren1,4, Ingrid Susanne Gribbestad1
1Department of Circulation and Medical
Imaging, Norwegian University of Science and Technology (NTNU), Trondheim,
Norway; 2Department of Oncology, Haukeland University Hospital,
Bergen, Norway; 3University of Bergen, Bergen, Norway; 4Department
of Oncology, St.Olav University Hospital, Trondheim, Norway
HR
MAS MR metabolic profiling was performed in paired samples from locally
advanced breast cancer patients obtained pre (n=19) and post (n=19)
doxorubicine treatment. PLSDA analysis
of HR MAS spectra showed classification between patients with long time
survival (≥5 years), and patients who died of cancer recurrence within
5 years. Our results suggest distinct metabolic profiles of these two patient
groups. High tCho, most significant GPC, levels before treatment correlated
to long time survival, while high glycine and lactate levels were associated
with poorer outcome.
Keywords